As clearly demonstrated by the examples of gliomas and AML with the oncogenic metabolite d-2-hydroxyglutarate, the establishment of RCG, even concomitantly with OXPHOS glutaminolysis (note that this mode does not require IDH2 and aconitase reactions), helps to accelerate the malignant phenotype. The gene discussed is IDH2; the disease is acute myeloid leukemia.